Publications by authors named "S Yossi"
Article Synopsis
- The study focuses on improving lung stereotactic body radiotherapy (SBRT) by using the deep inspiration breath hold (DIBH) technique alongside surface guided radiation therapy (SGRT), addressing challenges like tumor motion and delivery efficiency.
- A retrospective analysis was conducted on 13 lung SBRT patients, examining the correlation between surface positions monitored by SGRT and the actual internal tumor position, with a goal of achieving precise treatment delivery.
- Results showed minimal tumor motion during treatment and significant reductions in the doses received by both planned tumor volumes and surrounding healthy lung tissue, indicating the effectiveness of DIBH and SGRT in enhancing treatment outcomes.
Article Synopsis
- * Lobectomy surgery is the standard treatment for T1-T2 localized non-small cell lung carcinoma, while segmentectomy may be considered for patients with compromised respiratory health.
- * For patients who are inoperable or have poor lung function, stereotactic radiotherapy offers a high local control rate (85-95%) over 3-5 years, and research is ongoing to assess factors that influence these outcomes.
Ovarian cancer is the fifth most common cancer in women in France with 4714 new cases in 2017. More than 70% of patients whose disease is initially locally advanced will present locoregional or distant recurrence. Therapeutic options in this situation are not consensual.
View Article and Find Full Text PDFPrimitive lymphomas of the bone are exceptional tumors, representing 4% of all non-Hodgkin lymphomas. The location at the skull remains the rarest. We report the case of a 56 year old patient with lytic lesions in the skull of a small cell lymphoma B, treated with primary chemotherapy and intensity-modulated radiotherapy in arctherapy with a dose of 30Gy in 15 fractions.
View Article and Find Full Text PDFConcurrent radiochemotherapy (CRC) is a standard treatment in patients with inoperable locoregionally advanced ear-nose-throat (ENT) cancer. We report the safety and efficacy of CRC with daily fractionated 5-fluorouracil and cisplatin ('F' 5FU-CDDP) in a monocentric retrospective cohort. From January 2006 to August 2012, all patients with unresectable (or inoperable) nonmetastatic locoregionally advanced ENT cancer treated curatively by means of radiotherapy (normal fractionated 70 Gy to the macroscopic tumor and prophylactic 50 Gy) with three courses (week 1-week 4-week 7) of 'F' 5FU-CDDP regimen (800 mg/m/day of 5-fluorouracil and 20 mg/m/day of CDDP from day 1 to day 4) were included.
View Article and Find Full Text PDF